RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Funding-wise, it's still not clear where the company stands for 2016. While the Dronabinol Phase 2b is fully funded by the NIH, the 10-K says the recently started CX-1739 RD trial will cost $750 K.

Even though they raised $1.4 mil in 2015, if I'm reading the 10-K correctly, they had only $53 K at year end 2015, and raised $195 K in the first quarter of 2016. So I must either be missing something, or there will be significant funding news soon -


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121533545


>> The Company expects to incur approximately $750,000 of direct costs in 2016 with respect to this clinical trial, and to complete the clinical trial in approximately four months <<


>> Company raised aggregate gross proceeds of approximately $1,405,000 in the final closing of a convertible note and warrant offering that commenced in 2014 and concluded in 2015 <<


>> At December 31, 2015, the Company had cash aggregating $53,199 <<


>> During the first quarter of 2016, the Company raised an additional approximately $195,000 from the sale of units of common shares and warrants. <<


>> The Company will need to continue to raise additional capital to be able to pay its obligations and fund its business activities going forward <<